Enhancement of FK-506 activities by ganglioside (GM3) in vivo.
Influence of FK-506 and ganglioside (GM3) on acquired immunity to Hymenolepis nana reinfection was examined in BALB/c mice. Treatment of mice with FK-506 abolished the acquired immunity to challenge infection with eggs of H. nana when the agent was injected inraperitoneally at daily doses of 9.0 to 11.0 mg/kg (but not 8.5 mg/kg) on days -1, 0, 1, 2, and 3 relative to the challenge. Intravenous injection of GM3 at a daily dose of 10.0 mg/kg could not produce an immunosuppressive effect on the acquired immunity. Combination treatment with 8.5 mg/kg/day FK-506 and 10.0 mg/kg/day of GM3 inhibited the acquired immunity. These results suggest that GM3 will be a good candidate for a clinical supplementary immunosuppressive agent.
Matsuo
S
S
Department of Clinical Haematology, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.
Okamoto
K
K
D000818:Animals; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005679:G(M3) Ganglioside / Q000627:therapeutic use*; D006925:Hymenolepiasis / Q000276:immunology / Q000628:therapy*; D007111:Immunity, Cellular; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D016559:Tacrolimus / Q000627:therapeutic use*
D005679:G(M3) Ganglioside; D007166:Immunosuppressive Agents; D016559:Tacrolimus